The Technology Strategy Board is investing over £5 million to support British companies’ research and development of new regenerative medicine products, tools and technologies.
TSB is investing a total of £3.6 million across 16 therapeutics R&D projects and a further £1.6 million in 12 feasibility studies in related tools and technologies. The funding for therapeutics research will enable the companies involved to accelerate product development to take advantage of future market opportunities. Meanwhile, the funding for the feasibility studies…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
